Compare ADMA Biologics Inc (ADMA) vs Nokia Corp (NOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Nokia Corp — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Nokia Corp trades at $11.75 (market cap $66.24B). The key difference: Nokia Corp is far larger — about 31.1× ADMA Biologics Inc's market cap, and Nokia Corp pays a 1.38% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NOK | |
|---|---|---|
Market Cap | $2.13B | $66.24B |
Sector | Health | Technology |
52-Week High | $20.38 | $16.83 |
52-Week Low | $7.60 | $4.05 |
Enterprise Value | $2.20B | $63.06B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Nokia (NOK) trades at $11.85, down 1.74% amid a bearish technical signal, despite strong year-to-date performance. The company shows mixed fundamentals with a high P/E of 78.47 but recent earnings beats and a 44.12% gross margin. Recent news highlights Nokia's strategic pivot to AI infrastructure, including partnerships with Nvidia and Amazon Web Services, driving investor optimism about future growth potential in network modernization and data center markets.
Outlook remains cautiously optimistic with a consensus price target of $18.00 representing 52% upside, though high valuation and recent earnings miss pose risks. The stock's direction hinges on execution of AI initiatives and Q2 2026 earnings results due July 23, with technical indicators suggesting near-term consolidation near current support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
